Skip to main content
. 2018 May 20;11:1756286418774338. doi: 10.1177/1756286418774338

Figure 1.

Figure 1.

CONSORT patient flow diagram for PREFERMS.

*More than one reason for exclusion could be recorded for a patient.

CONSORT, Consolidated Standards of Reporting Trials; iDMT, injectable disease-modifying therapy; PREFERMS, Prospective, Randomized, active-controlled, open-label study to Evaluate patient retention on Fingolimod versus approved first-line disease modifying therapies in adults with Relapsing remitting Multiple Sclerosis.